Phase-II Clinical Trial for Clot-busting Drug Soon

India on Thursday announced the start of Phase-II human clinical trials of an indigenously developed clot-busting drug and upon successful development it would be the first patented biopharmaceutical drug developed in the country.

Published: 14th February 2014 06:00 AM  |   Last Updated: 14th February 2014 01:40 AM   |  A+A-

India on Thursday announced the start of Phase-II human clinical trials of an indigenously developed clot-busting drug and upon successful development it would be the first patented biopharmaceutical drug developed in the country.

The Drugs Controller General of India (DGCI) has granted permission to conduct human clinical trials to test the efficacy of Clot Specific Streptokinase (CSSK) in heart attack patients.

According to scientists, CSSK would be a much cheaper and affordable alternative to the currently available expensive thrombolytic drugs and will thus address the needs of the larger masses of the country.

Besides, it is unique as it has a hugely reduced risk of bleeding during the treatment, which makes it a distinctively improved drug compared to several currently employed thrombolytic drugs where the risk of bleeding exists to varying degrees.

The drug has been developed as a public-private partnership between CSIR-Institute of Microbial Technology (CSIR-IMTECH) and Nostrum Pharmaceuticals of the US.

Announcing the Phase-II trials, T Ramasami Secretary Department of Science and Technology, said this has been an exemplary and diligent pursuit of translational science from lab to the very threshold of clinic.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp